Table 3 Results of Cox proportional hazards regression for PFS and OS.

From: Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy

Factor

PFS

OS

Hazard ratio

P value

Hazard ratio

P value

Age ≥ 65 years

1.68 (1.10–2.58)

0.02

6.65 (2.88–15.36)

< 0.001

B symptoms

1.26 (0.84–1.88)

0.26

1.67 (1.04–2.67)

0.03

Bone marrow invasion

1.31 (0.81–2.10)

0.27

1.14 (0.61–2.10)

0.68

Extranodal lesions ≥ 2

1.07 (0.66–1.74)

0.78

1.09 (0.59–2.03)

0.78

Non-GCB

1.54 (1.09–2.18)

0.01

1.14 (0.75–1.74)

0.53

PS ≥ 2

1.36 (0.69–2.68)

0.37

1.43 (0.67–3.04)

0.35

Post-treatment sIL-2R > UNL

2.57 (1.79–3.71)

< 0.001

3.15 (2.04–4.86)

< 0.001

Pre-treatment sIL-2R > UNL

1.25 (0.77–2.03)

0.37

1.36 (0.71–2.57)

0.35

Stage III or IV

2.02 (1.34–3.04)

0.01

1.49 (0.89–2.48)

0.13

  1. GCB germinal centre B-cell-like type, high-int high-intermediate, IPI international prognostic index, OS overall survival, PFS progression-free survival, PS performance status, sIL-2R soluble interleukin-2 receptor, UNL upper normal limit.
Back to article page